NIGMS Administrative Supplemental Awards

The National Institutes of General Medical Sciences (NIGMS) provides funds for administrative supplements to current awardees on the Institutional Development Award (IDeA) program including Centers of Biomedical Research Excellence (COBRE), IDeA Networks of Biomedical Research Excellence (INBRE) and IDeA Networks for Clinical and Translational Research (IDeA-CTR) awards.

Administrative Supplemental Award for Equipment Purchases for Select NIGMS-Funded Awards

(May, 2024, National Institute of General Medical Sciences - NIGMS)

Administrative Supplements (AS) for Equipment Purchases for Select NIGMS-Funded Awards are "intended for the purchase of needed equipment that will enhance user access to and/or the impact of the resource" for centers, resources and core facilities. The MCHD-COBRE was awarded an AS to purchase an AmiHTX High Efficiency In Vivo Imaging System instrument. The AmiHTX will allow higher resolution imaging, additional capabilities including x-ray imaging, enhanced wavelength detection and data analysis capabilities. This instrument is the only one of its type in central Mississippi and it will be regularly used to provide animal imaging capabilities to collaborators around the state.

Administrative Supplements for Research on Women's Health in the IDeA States

(June 2024, National Institute of General Medical Sciences - NIGMS)

Dr. Drazen Raucher, Professor, Department of Cell and Molecular Biology received NIGMS Administrative Supplement Award entitled, "Investigating Sex-Specific Mechanisms of a Small Molecule Drug in Huntington's Disease. This project addresses a critical need for improved treatments in Huntington's disease (HD), a devastating neurodegenerative disorder. Dr. Raucher and his team are developing GLYN122, a novel small molecule therapy, to lower mutant huntingtin protein (mHTT) levels and alleviate HD symptoms. As they investigate GLYN122's unique advantages and conduct a comprehensive analysis of sex-specific responses, their research aligns with the "Advancing Science for the Health of Women" initiative and will utilize MCHD-COBRE infrastructure to delve into the molecular and physiological mechanisms underpinning these sex-specific responses to GLYN122.